NeoGenomics, Inc. announced the commercial availability of two new tests, expanding its cancer portfolio of innovative products. These include Neo Comprehensive?? - Heme Cancers, a next-generation sequencing (NGS) panel with a comprehensive genomic profile of hematologic malignancies, and Early-stage Non-Small Cell Lung Cancer (NSCLC) Panel, a therapy selection panel designed specifically for early-stage NSCLC patients.

Neo Comprehensive - Heme Cancers is NeoGenomics' largest, most comprehensive heme NGS panel with broad coverage of genes associated with hematologic cancers. It further enhances NeoGenomics' extensive test menu for heme testing, especially the NGS portfolio, strengthening the company's position as a leading laboratory in heme oncology services. The Early-stage NSCLC Panel is NeoGenomics' most focused early-stage lung cancer panel to date, detecting genomic alterations and gene expression in key biomarkers that are relevant in diagnosis, therapy selection, prognosis, and clinical trials.

The Panel provides new, easy-to-interpret reports and a 7 day turn-around time, offering clinicians the ability to easily order the evidence-based set of concise, targeted, and actionable markers in a specific panel to support the management of their patients with lung cancer, at earlier stages of diagnosis. About Neo Comprehensive?? - Hemo Cancers: Heme Cancers is a comprehensive genomic profile (CGP) analyzing 433 genes relevant to most forms of hematologic malignancy from myeloid and lymphoid lineages, detecting SNVs (single nucleotide variants), InDels (insertions and deletions), CNVs (copy number variants), and fusions utilizing DNA and RNA NGS methods.

This panel is aligned with the latest guidelines and the WHO 5th Edition Classification of Haematolymphoid Tumours. It can provide key diagnostic information, including critical molecular determinations affecting therapeutic approaches, aid in risk stratification, predicting prognosis, and can be used in clinical research. About Early-stage NSCLC panel: The Early-stage NSCL C Panel is available as an enhancement of existing single-gene tests by simplifying ordering and increasing standardization of evidence-based multi-biomarker testing.

Combining information about genetic alterations and PD-L1 expression provides the complete picture for targeted therapy decisions that provide the best outcomes for patients.